Here, we demonstrated that the administration of CaD, an angiopreventive drug clinically approved for the treatment of diabetic retinopathy [30], inhibited oxidative stress as revealed by decreased MDA levels and the increased activity of the antioxidative enzymes SOD, GPx, and CAT in brain homogenates. The gene discussed is SOD1; the disease is diabetic retinopathy.